Navigation

Summary of Results

Health Topic:   Digestive system
Guidance:   Crohn's disease - infliximab (review) and adalimumab (review of TA40)
Description:   The summary of the published technology appraisal on Crohn's disease - infliximab (review) and adalimumab (review of TA40). It links to the published guidance and key documents.

NICE implementation uptake reports

Implementation uptake report Assessment Published Date Coverage

External literature

External literature Assessment Coverage

Royal College of Physicians (2012) The UK inflammatory bowel disease audit: interim report of the biological therapy audit - Interim national report

Description: This interim report informs of the on-going progress and development of the biologics audit from the UK inflammatory bowel disease audit. The audit measures the efficacy, safety and appropriate use of biologics therapies (Infliximab and Adalimumab). Interim findings are based on data submitted from 12 September 2011 to 29 February 2012 and suggest that the vast majority of biological therapy is being used in accordance with NICE recommendations.

Practice appears to be in line with guidance National

Royal College of Physicians (2013) UK Inflammatory Bowel Disease (IBD) audit: National clinical audit of biological therapies - Paediatric national report

Description: This audit measures the appropriate use of biological therapies in paediatric patients with inflammatory bowel disease in the UK. Data is included for patients that were newly started on biological therapies between 12/09/11 and 28/02/13 from 19/25 specialist paediatric IBD sites and two additional paediatric sites (21 in total) Results found that only 11% of patients were recorded as having been appropriately prescribed anti-TNF treatment, when compared against NICE TA187.

Practice appears not to be in line with guidance National

Royal College of Physicians (2013) UK Inflammatory Bowel Disease (IBD) audit: National clinical audit of biological therapies - Adult national report

Description: This audit measures the appropriate use of biological therapies in patients with inflammatory bowel disease in the UK. Data is included for patients that were newly started on biological therapies between 12/09/11 and 28/02/13. Results found that for patients with Crohn?s disease, 85% (800/937) of patients were treated with conventional therapy at or prior to commencement of biological therapy and 57% (260/457) of patients on biological therapy were appropriately prescribed anti-TNFs.

Doubts about or mixed impact in practice National

This page was last updated: 01 August 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.